BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Z, Wang K, Yang H, Han Z, Tao J, Chen H, Ge Y, Guo M, Suo C, Wei JF, Tan R, Gu M. Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients. Oncotarget 2017;8:100079-94. [PMID: 29245962 DOI: 10.18632/oncotarget.21941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Ning Z, Liu K, Xiong H. Roles of BTLA in Immunity and Immune Disorders. Front Immunol 2021;12:654960. [PMID: 33859648 DOI: 10.3389/fimmu.2021.654960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Núñez L, Marrón-Liñares GM, Crespo-Leiro MG, Barge-Caballero E, Álvarez-López E, Suarez-Fuentetaja N, Paniagua-Martin MJ, Pombo J, Muñiz J, Tan CD, Rodríguez ER, Vázquez-Rodríguez JM, Hermida-Prieto M. AGT haplotype in ITGA4 gene is related to antibody-mediated rejection in heart transplant patients. PLoS One 2019;14:e0219345. [PMID: 31335901 DOI: 10.1371/journal.pone.0219345] [Reference Citation Analysis]
3 Grywalska E, Pasiarski M, Góźdź S, Roliński J. Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. Onco Targets Ther 2018;11:6505-24. [PMID: 30323625 DOI: 10.2147/OTT.S150817] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
4 Mardomi A, Mohammadi N, Khosroshahi HT, Abediankenari S. An update on potentials and promises of T cell co-signaling molecules in transplantation. J Cell Physiol 2020;235:4183-97. [PMID: 31696513 DOI: 10.1002/jcp.29369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]